Another variant with a substantial difference in MAF between admixture groups was ABCG2 p.Q141K, which affects the response to rosuvastatin (Tomlinson et al., 2010), the most cost-effective option for dyslipidemia treatment in Mexico (Briseño and Mino-León, 2010). The gene discussed is ABCG2; the disease is metabolic syndrome.